Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

ClinicalTrials.gov ID: NCT03118947

Public ClinicalTrials.gov record NCT03118947. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 4:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 52-Week Open-Label Extension Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease

Study identification

NCT ID
NCT03118947
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ACADIA Pharmaceuticals Inc.
Industry
Enrollment
79 participants

Conditions and interventions

Interventions

  • Pimavanserin Drug

Drug

Eligibility (public fields only)

Age range
50 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 22, 2017
Primary completion
Feb 24, 2019
Completion
Feb 24, 2019
Last update posted
Apr 8, 2020

2017 – 2019

United States locations

U.S. sites
17
U.S. states
10
U.S. cities
17
Facility City State ZIP Site status
ATP Clinical Research, Inc. Costa Mesa California 92626
Neuro-Pain Medical Center Fresno California 93710
Neurology Center of North Orange County Fullerton California 92835
Pacific Clinical Research Network San Diego California 92103
Clinical Research Unit Washington D.C. District of Columbia 20007
Parkinson's Disease and Movement Disorders Center of Boca Raton Boca Raton Florida 33486
Quantum Laboratories Inc. Deerfield Beach Florida 33064
Miami Jewish Health Systems Miami Florida 33137
Collier Neurologic Specialists LLC Naples Florida 34105
Acadia Hospital Bangor Maine 04401
Alzheimer's Disease Center Quincy Massachusetts 02169
Memory Enhancement Center of America, Inc. Eatontown New Jersey 07724
Bio Behavioral Health Toms River New Jersey 08755
ANI Neurology, PLLC dba Alzheimer's Memory Center Charlotte North Carolina 28270
Abington Neurological Associates, Ltd. Willow Grove Pennsylvania 19090
Insite Clinical Research, LLC DeSoto Texas 75115
Pharmaceutical Research Associates, Inc. Salt Lake City Utah 84107

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 11 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03118947, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Apr 8, 2020 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03118947 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →